1. Home
  2. LNKB vs SERA Comparison

LNKB vs SERA Comparison

Compare LNKB & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LNKB
  • SERA
  • Stock Information
  • Founded
  • LNKB 2018
  • SERA 2008
  • Country
  • LNKB United States
  • SERA United States
  • Employees
  • LNKB N/A
  • SERA N/A
  • Industry
  • LNKB
  • SERA Precision Instruments
  • Sector
  • LNKB
  • SERA Health Care
  • Exchange
  • LNKB Nasdaq
  • SERA Nasdaq
  • Market Cap
  • LNKB 236.7M
  • SERA 258.3M
  • IPO Year
  • LNKB N/A
  • SERA 2021
  • Fundamental
  • Price
  • LNKB $6.35
  • SERA $6.66
  • Analyst Decision
  • LNKB Hold
  • SERA
  • Analyst Count
  • LNKB 1
  • SERA 0
  • Target Price
  • LNKB $7.50
  • SERA N/A
  • AVG Volume (30 Days)
  • LNKB 50.8K
  • SERA 135.2K
  • Earning Date
  • LNKB 10-25-2024
  • SERA 11-06-2024
  • Dividend Yield
  • LNKB 4.72%
  • SERA N/A
  • EPS Growth
  • LNKB N/A
  • SERA N/A
  • EPS
  • LNKB N/A
  • SERA N/A
  • Revenue
  • LNKB $68,142,000.00
  • SERA $107,000.00
  • Revenue This Year
  • LNKB N/A
  • SERA N/A
  • Revenue Next Year
  • LNKB $4.03
  • SERA $2,020.00
  • P/E Ratio
  • LNKB N/A
  • SERA N/A
  • Revenue Growth
  • LNKB 101.22
  • SERA N/A
  • 52 Week Low
  • LNKB $5.86
  • SERA $1.56
  • 52 Week High
  • LNKB $8.29
  • SERA $12.36
  • Technical
  • Relative Strength Index (RSI)
  • LNKB 46.89
  • SERA 39.99
  • Support Level
  • LNKB $6.27
  • SERA $6.87
  • Resistance Level
  • LNKB $6.46
  • SERA $7.27
  • Average True Range (ATR)
  • LNKB 0.14
  • SERA 0.48
  • MACD
  • LNKB -0.01
  • SERA -0.10
  • Stochastic Oscillator
  • LNKB 20.69
  • SERA 0.00

About LNKB LINKBANCORP Inc.

Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Share on Social Networks: